• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.

作者信息

Genre Fernanda, López-Mejías Raquel, Miranda-Filloy José A, Ubilla Begoña, Carnero-López Beatriz, Gómez-Acebo Inés, Blanco Ricardo, Ochoa Rodrigo, Rueda-Gotor Javier, Pina Trinitario, González-Juanatey Carlos, Llorca Javier, González-Gay Miguel A

机构信息

Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.

出版信息

Ann Rheum Dis. 2014 May;73(5):941-3. doi: 10.1136/annrheumdis-2013-204484. Epub 2013 Dec 9.

DOI:10.1136/annrheumdis-2013-204484
PMID:24323393
Abstract
摘要

相似文献

1
Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.抗肿瘤坏死因子α治疗可降低非糖尿病性强直性脊柱炎患者血清视黄醇结合蛋白4水平。
Ann Rheum Dis. 2014 May;73(5):941-3. doi: 10.1136/annrheumdis-2013-204484. Epub 2013 Dec 9.
2
Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.抗肿瘤坏死因子-α疗法可调节非糖尿病强直性脊柱炎患者血清血管生成素-2水平。
Ann Rheum Dis. 2013 Jul;72(7):1265-7. doi: 10.1136/annrheumdis-2012-203169. Epub 2013 Mar 12.
3
Treatment of ankylosing spondylitis with infliximab.英夫利昔单抗治疗强直性脊柱炎
Ann Rheum Dis. 2001 Dec;60(12):1159-60. doi: 10.1136/ard.60.12.1159.
4
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎：系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
5
Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.非糖尿病性强直性脊柱炎患者接受 TNF-α 拮抗剂治疗后脂联素和抵抗素的血清水平。
Clin Exp Rheumatol. 2013 May-Jun;31(3):365-71. Epub 2013 Jan 23.
6
[New results from studies of therapy of ankylosing spondylitis with infliximab].[英夫利昔单抗治疗强直性脊柱炎的研究新成果]
Z Rheumatol. 2003 Apr;62(2):108-9. doi: 10.1007/s00393-003-0501-3.
7
Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.对马克西莫维奇所著《支持TNF制动假说有效性的证据》的回应
Ann Rheum Dis. 2013 Dec;72(12):e32-3. doi: 10.1136/annrheumdis-2013-204493. Epub 2013 Sep 20.
8
Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?肿瘤坏死因子阻滞剂能否抑制强直性脊柱炎未来结构损伤的进展？
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
9
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.英夫利昔单抗治疗强直性脊柱炎无效与抗体形成有关。
Ann Rheum Dis. 2007 Jan;66(1):133-4. doi: 10.1136/ard.2006.057745.
10
Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.维持英夫利昔单抗治疗强直性脊柱炎的临床应答：一项 6 年的长期研究。
Joint Bone Spine. 2010 Jul;77(4):325-9. doi: 10.1016/j.jbspin.2010.02.014. Epub 2010 May 8.

引用本文的文献

1
Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases.脂肪细胞因子在炎症和退行性肌肉骨骼疾病的病理生理学中的作用。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211015034. doi: 10.1177/20587384211015034.
2
Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study.循环视黄醇结合蛋白4作为强直性脊柱炎治疗反应的潜在生物标志物：一项基于阵列的比较研究
Front Pharmacol. 2020 Mar 10;11:231. doi: 10.3389/fphar.2020.00231. eCollection 2020.
3
Subclinical atherosclerosis: A hidden threat for patients with ankylosing spondylitis.
亚临床动脉粥样硬化：强直性脊柱炎患者的潜在威胁。
Anatol J Cardiol. 2019 Sep;22(4):192-193. doi: 10.14744/AnatolJCardiol.2019.78703.
4
Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-α antagonists and healthy matched controls.接受肿瘤坏死因子-α拮抗剂治疗的强直性脊柱炎患者与健康对照者在颈动脉粥样硬化方面的差异。
Medicine (Baltimore). 2018 Jul;97(27):e11250. doi: 10.1097/MD.0000000000011250.
5
Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.代谢综合征与慢性关节炎：抗TNF-α治疗的效果
Clin Exp Med. 2015 Nov;15(4):433-8. doi: 10.1007/s10238-014-0323-4. Epub 2014 Nov 27.
6
IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.在接受抗TNF-α治疗的非糖尿病强直性脊柱炎患者中，IGF-1水平与ADMA水平呈负相关。
Biomed Res Int. 2014;2014:671061. doi: 10.1155/2014/671061. Epub 2014 Sep 11.
7
Cardiovascular involvement in autoimmune diseases.自身免疫性疾病中的心血管受累情况。
Biomed Res Int. 2014;2014:367359. doi: 10.1155/2014/367359. Epub 2014 Jul 22.
8
Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.因抗TNF-α治疗而疾病活动度低的强直性脊柱炎患者的TRAIL水平高于对照组：一种潜在的代偿效应。
Mediators Inflamm. 2014;2014:798060. doi: 10.1155/2014/798060. Epub 2014 May 21.
9
Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.强直性脊柱炎患者的脂肪因子、内皮激活生物标志物与代谢综合征
Biomed Res Int. 2014;2014:860651. doi: 10.1155/2014/860651. Epub 2014 Mar 18.
10
Retinol binding protein 4 concentrations relate to enhanced atherosclerosis in obese patients with rheumatoid arthritis.视黄醇结合蛋白 4 浓度与肥胖类风湿关节炎患者动脉粥样硬化的增强有关。
PLoS One. 2014 Mar 20;9(3):e92739. doi: 10.1371/journal.pone.0092739. eCollection 2014.